# MDA Malaysia Medical Device Postmarket Requirements

Last reviewed: October 15, 2026

Post-market medical device compliance in Malaysia includes renewals, modifications, postmarket surveillance, and vigilance.

Regulatory Overview

## Overview of postmarket requirements in Malaysia

Once you have obtained market authorization for your medical device from the [Medical Device Authority (MDA)](https://www.pureglobal.com/glossary/malaysia-mda) in Malaysia, you must be proactive to maintain regulatory compliance. Postmarket compliance obligations include timely renewals of your device registration, notifying MDA of any changes or modifications to your device, establishing a postmarket surveillance (PMS) system, and reporting adverse events involving your device, also known as vigilance.

### Renewals

MDA device registrations must be renewed every five (5) years. Renewal applications should be submitted through the MeDC@St application system up to one year before the expiration date of your current registration.

### Modifications

Some device changes or modifications can be implemented via a change notification to MDA while others may require a new registration submission. There are three categories of modifications. Category 1 modifications comprise significant changes that may affect the safety and performance of the device, such as its intended use or risk classification, and require a new registration application. Category 2 modifications require MDA approval before implementation; specific documentation must be submitted via MeDC@St according to the type of modification. Category 3 changes can be implemented as soon as the necessary documentation is submitted to MDA via MeDC@St. Specific documentation and modification scenarios are addressed in MDA’s change notification [guidance](https://portal.mda.gov.my/index.php/documents/guidance-documents/2392-guidance-document-change-notification-for-registered-medical-device-4th-edition/file).

## Medical device postmarket surveillance and vigilance in Malaysia

Manufacturers selling medical devices in Malaysia must have a postmarket surveillance system in place to monitor the safety and performance of their device on the market. Postmarket requirements also include vigilance, which requires manufacturers to evaluate, document, and report adverse events involving their medical device registered in Malaysia.

Postmarket surveillance and vigilance requirements are laid out in the [Medical Device Act of 2012](https://www.mda.gov.my/index.php/documents/regulation/685-medical-device-act-2012-eng/file), [Medical Device Regulations of 2019](https://www.mda.gov.my/index.php/documents/regulation/1313-medical-device-regulations-duties-and-obligations-of-establishments-2019/file) (link in Bahasa Malaysia), and guidance documents that address required activities. These activities include:

-   [Distribution Records](https://www.mda.gov.my/index.php/documents/guidance-documents/1428-distribution-records-60-60-3june2020-1/file)
-   [Mandatory Problem Reporting](https://www.mda.gov.my/index.php/documents/guidance-documents/1476-mandatory-problem-reporting-60-60-10-june2020-2/file)
-   [Complaint Handling](https://www.mda.gov.my/index.php/documents/regulation/1313-medical-device-regulations-duties-and-obligations-of-establishments-2019/file)
-   [Field Corrective Actions (FCA)](https://www.mda.gov.my/index.php/documents/guidance-documents/1436-field-corrective-action-gdac-29june2020-syedited/file)
-   [Medical Device Recalls](https://www.mda.gov.my/index.php/documents/guidance-documents/1439-medical-device-recall-60-90-2july2020-edited-gdac-decision/file)

## Mandatory Problem Reporting Timelines for Medical Devices in Malaysia

Incidents involving your medical device must be reported to the MDA. Following the initial report, manufacturers are required to investigate the cause of the incident and conduct field corrective action (FCA), if necessary, to prevent a recurrence. All findings and outcomes of the investigation should be reported to MDA. MDA will review the report and you will receive a written letter from the MDA if the findings and corrective actions are acceptable.

Manufacturers and authorized representatives are obligated to report incidents as soon as they learn of them. Depending on the nature of the incident, reporting must occur within a mandatory timeline:

-   within 30 days for a reportable malfunction, deterioration or labeling/IFU inadequacy that has not caused death or serious deterioration but could do so if it recurred.
    
-   within 10 days if the incident has led to the death or a serious deterioration in the state of health of a patient, user or other person.
    
-   within 48 hours if the incident is a serious threat to public health.
    

## Local exposure and the current reporting channel

MDA's [mandatory problem reporting guidance](https://portal.mda.gov.my/index.php/industry/vigilance-unit/mandatory-problem-reporting) sets the reporting assessment. Check [MeDCReSt notices](https://medcrest.mda.gov.my/home), including the 8 May 2025 notice concerning incident submissions occurring outside Malaysia. Keep overseas signal review separate from whether a particular portal submission is required, and assess Malaysian field safety corrective action independently.

Maintain an incident register with awareness dates, affected models/lots, local distribution, severity rationale, initial report, investigation and follow-up. Link complaints to risk management and CAPA. Track the actual device registration and establishment licence expiries separately; neither renewal replaces the need to assess a design or labeling change.

How We Can Help

## Full MDA Support for a Simple Annual Fee

Plan your device registration, local representation and ongoing compliance with Pure Global.

[Contact us](https://www.pureglobal.com/contact)[Pricing](https://www.pureglobal.com/services/pricing?country=MY)

![Pure Global market entry support team](https://www.pureglobal.com/assets/owned/75037ea614--67ab304f89cb5422fdc63bc7__67ab304f89cb5422fdc63d5e_feature_5.webp)

## Frequently asked questions

### What are Malaysia’s initial problem-reporting time limits?

MDA guidance distinguishes a serious public-health threat, reportable death or serious deterioration, and other reportable events by severity, with initial limits of 48 hours, 10 days and 30 days respectively. Submit initial information promptly and complete follow-up under the applicable requirements.

### Must every overseas incident be submitted through MeDCReSt?

Review MDA’s current notice on discontinuation of incident submissions occurring outside Malaysia, together with local exposure and field-action requirements. Do not assume that either every foreign incident needs a routine local submission or that overseas safety information can be ignored.

### Are registration changes all handled by notification?

No. Classify the proposed change using the current effective MDA guidance. Some require approval before implementation, while other categories permit notification; substantial changes may require a different application. Record the decision before release.

## Single Process,  
Multiple Markets

When you partner with Pure Global, a single registration process opens doors to multiple countries. Our global subsidiaries make this streamlined path possible.

[

Argentina



](https://www.pureglobal.com/markets/argentina)

[

Australia



](https://www.pureglobal.com/markets/australia)

[

Bangladesh



](https://www.pureglobal.com/markets/bangladesh)

[

Brazil



](https://www.pureglobal.com/markets/brazil)

[

Canada



](https://www.pureglobal.com/markets/canada)

[

China



](https://www.pureglobal.com/markets/china)

[

Colombia



](https://www.pureglobal.com/markets/colombia)

[

Costa Rica



](https://www.pureglobal.com/markets/costa-rica)

[

Egypt



](https://www.pureglobal.com/markets/egypt)

[

European Union



](https://www.pureglobal.com/markets/european-union)

[

Hong Kong



](https://www.pureglobal.com/markets/hong-kong)

[

India



](https://www.pureglobal.com/markets/india)

[

Indonesia



](https://www.pureglobal.com/markets/indonesia)

[

Israel



](https://www.pureglobal.com/markets/israel)

[

Japan



](https://www.pureglobal.com/markets/japan)

[

Macau



](https://www.pureglobal.com/markets/macau)

[

Malaysia



](https://www.pureglobal.com/markets/malaysia)

[

Mexico



](https://www.pureglobal.com/markets/mexico)

[

New Zealand



](https://www.pureglobal.com/markets/new-zealand)

[

Pakistan



](https://www.pureglobal.com/markets/pakistan)

[

Peru



](https://www.pureglobal.com/markets/peru)

[

Philippines



](https://www.pureglobal.com/markets/philippines)

[

Saudi Arabia



](https://www.pureglobal.com/markets/saudi-arabia)

[

Singapore



](https://www.pureglobal.com/markets/singapore)

[

South Korea



](https://www.pureglobal.com/markets/south-korea)

[

Switzerland



](https://www.pureglobal.com/markets/switzerland)

[

Taiwan



](https://www.pureglobal.com/markets/taiwan)

[

Thailand



](https://www.pureglobal.com/markets/thailand)

[

UAE



](https://www.pureglobal.com/markets/uae)

[

United Kingdom



](https://www.pureglobal.com/markets/united-kingdom)

[

United States



](https://www.pureglobal.com/markets/united-states)

[

Vietnam



](https://www.pureglobal.com/markets/vietnam)

[Canonical page](https://www.pureglobal.com/markets/malaysia/mda-medical-device-postmarket-requirements)
